Mo
Morphic (Lilly)
Waltham MAFounded 2015120 employees
Private CapbiotechAcquiredGIImmunology
Platform: MORF-057 Integrin
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| MOR-1300 | MOR-1300 | Phase 1/2 | 2 | EZH2 | CholangiocarcinomaIPF | ||
| MOR-4433 | MOR-4433 | Phase 1/2 | 1 | GLP-1R | MMHCC |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)